Extracellular transportation of α-synuclein by HLA class II molecules
Biochemical and Biophysical Research Communications · 2023-02 · 644 · 25-33
DOI: 10.1016/j.bbrc.2022.12.082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023-02. Verfasst von Tatsuhiko Ozono und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan; Laboratory of Immunochemistry, …. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Japan Science and Technology Agency, Core Research for Evolutional Science and Technology, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive accumulation of α-synuclein aggregates in form of Lewy bodies. Genome-wide association studies have revealed that human leukocyte antigen (HLA) class II is a PD-associated gene, although the mechanisms linking HLA class II and PD remain elusive. Here, we identified a novel function of HLA class II in the transport of intracellular α-synuclein to the outside of cells. HLA class II molecules and α-synuclein formed complexes and moved to the cell surface at various degrees among HLA-DR alleles. HLA-DR with a DRB5∗01:01 allele, a putative PD-risk allele, substantially translocated normal and conformationally abnormal α-synuclein to the cell surface and extracellular vesicles. α-Synuclein/HLA class II complexes were found in A2058 melanoma cells, which express intrinsic α-synuclein and HLA-DR with DRB5∗01:01. Our findings will expand our knowledge of unconventional HLA class II function from autoimmune diseases to neurodegenerative disorders, shedding light on the association between the GWAS-prioritized PD-risk gene HLA-DR and α-synuclein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan; Laboratory of Immunochemistry, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka,…
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Laboratory of Immunochemistry, Immunology Frontier Research Center, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan; Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka Univers…
- Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Neurology, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan. Electronic address: hmochizuki@neurol.med.osaka-u.ac.jp.
Förderung
- Japan Science and Technology Agency
- Core Research for Evolutional Science and Technology
- Japan Agency for Medical Research and Development
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science
Zitieren
APA
Ozono, T., Kimura, Y., Suenaga, T., Beck, G., Jinno, J., Aguirre, C., Ikenaka, K., Krainc, D., Mochizuki, H., & Arase, H. (2023). Extracellular transportation of α-synuclein by HLA class II molecules. Biochemical and Biophysical Research Communications, 644, 25-33. https://doi.org/10.1016/j.bbrc.2022.12.082
Vancouver
Ozono T, Kimura Y, Suenaga T, Beck G, Jinno J, Aguirre C, et al. Extracellular transportation of α-synuclein by HLA class II molecules. Biochemical and Biophysical Research Communications. 2023;644:25-33. doi:10.1016/j.bbrc.2022.12.082
BibTeX
@article{Ozono2023,
author = {Ozono, Tatsuhiko and Kimura, Yasuyoshi and Suenaga, Tadahiro and Beck, Goichi and Jinno, Jyunki and Aguirre, César and Ikenaka, Kensuke and Krainc, Dimitri and Mochizuki, Hideki and Arase, Hisashi},
title = {Extracellular transportation of α-synuclein by HLA class II molecules},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
volume = {644},
pages = {25--33},
doi = {10.1016/j.bbrc.2022.12.082}
}
EUVIMED